CIHR & 4YF Scholar, BC Cancer Rising Star, #PhDcandidate in #oncology at @ubcmedicine, #CARTcells #immunotx #bloodcancer #myeloma | Likes 🧗🏻🎸⛷️🏋🏻| 🇨🇦🇵🇭
Vancouver, BC
Joined November 2019
- Tweets542
- Following577
- Followers236
- Likes2.2K
Pinned Tweet
Delighted to announce that my first ever review has been published in @FrontImmunol! We review how the TME can restrict CAR T-cells and discuss the novel strategies aiming to overcome the TME and reduce toxicity frontiersin.org/articles/10.… @ScienceVancity @UBCmedicine @BCCancer
Lorenzo Lindo retweeted
Sending lots of love to my friends in Calgary and Vancouver ❤️ Someone please scoop up the incredibly talented and great people that are now available for the next generation of media.
Lorenzo Lindo retweeted
A holy grail for our lab has been tracking myeloid cells in human tumors in the same way that we track T and B cells with TCR/BCR.
@vincentzliu and @CalebLareau solved it!
We developed Mitotrek using scATAC-seq + mitochondrial DNA to do exactly this. Using Mitotrek, we find that new myeloid cells clones constantly infiltrate the tumor via circulating monocytes — and that their macrophage or dendritic cell fate is epigenetically programmed before tumor entry.
@10xGenomics @parkerici @CancerResearch @TheMarkFdn
cell.com/cancer-cell/fulltex…
Congratulations Dr Rempel!
Excited to share that our publication exploring the challenges and considerations when managing NLUTD in aging men with SCI was recently published in @NatRevUrol! Tremendous work by everyone at @ICORD_SCI and our collaborators.
nature.com/articles/s41585-0…
Just read your final article - it's so hard to put into words the appreciation I have for your courage throughout your journey, and the dedication you have put towards advocacy. It was an absolute pleasure to have known you. Rest easy, friend.
There comes a time to say Farewell.
Winding Up or Winding Down journey.anguspratt.ca/windin…
Lorenzo Lindo retweeted
Online Now: Engineered natural killer cells for cancer therapy dlvr.it/TNrrl8
Lorenzo Lindo retweeted
BREAKING NEWS
The 2025 #NobelPrize in Physiology or Medicine has been awarded to Mary E. Brunkow, Fred Ramsdell and Shimon Sakaguchi “for their discoveries concerning peripheral immune tolerance.”
Lorenzo Lindo retweeted
Nature research paper: In vivo CRISPR screens identify modifiers of CAR T cell function in myeloma
go.nature.com/4nLn9o5
Lorenzo Lindo retweeted
🤯Three (!!!) new papers today in @ScienceMagazine on the application of generative AI for the de novo design of peptide/HLA binding molecules! Completely unique 3D structure and binding mode compared with natural TCRs and TCR mimics! Links to papers 👇
Lorenzo Lindo retweeted
🧵1/🚨 New in Blood Advances: Nanobody-based BCMA CAR-T therapy (S103) shows high efficacy & manageable safety in relapsed/refractory plasma cell myeloma.
🧵2/🧬 Novel CAR-T Design
S103 uses dual nanobody VHHs (dVHHs) instead of scFvs:
🔹 Enhanced affinity/specificity
🔹 Dual-epitope recognition
🔹 Lower immunogenicity
🔹 Better pharmacokinetics
💡 Small, stable, & precise
#mmsm #MedEd #myeloma #MedTwitter #USMIRC @USMIRCNEWS @OncoAlert #سرطان_الدم #المايلوما #Oncology #CAR_T
Lorenzo Lindo retweeted
5 papers all computational biologists should read 🧵
1. A Quick Guide to Organizing Computational Biology Projects
journals.plos.org/ploscompbi…
Lorenzo Lindo retweeted
🧵1/ Real-World Head-to-Head: Cilta-cel vs. Ide-cel in Myeloma 🧬
A prospective biomonitoring study (N=39) dives deep into the biologic and clinical differences between 2 BCMA CAR-Ts: cilta-cel and ide-cel. Results are eye-opening.
#mmsm #MedEd #myeloma #MedTwitter #USMIRC @USMIRCNEWS @OncoAlert #سرطان_الدم #المايلوما
Lorenzo Lindo retweeted
This week we publish in @NatureBiotech "High-precision cytosine base editors by evolving nucleic-acid-recognition hotspots in deaminase". In this work, we show that both nucleotide and context specificity of deaminases can be reprogrammed by hotspot-focused directed evolution 1/n
Lorenzo Lindo retweeted
In-vivo CAR Ts for myeloma are going to come fast and furious. These products are engineering marvels.
ESO-T01 (EsoBiotec) is an anti-BCMA in-vivo CAR T that:
1) Delivers the CAR transgene to endogenous T-cells, reprogramming them to CAR T cells in situ
2) Overexpress CD47 to reduce phagocytosis
3) MHC class I knocked out to reduce GVHD
4) Once transformed to CAR T, has anti-BCMA variable domain (nanobody derived), CD8 hinge and transmembrane domain, 4-1BB costim domain, and CD3-zeta activation domain.
5) No lymphodepletion needed + off-the-shelf
Lorenzo Lindo retweeted
1/ Working with big data in R?
Your wrangling just got a massive upgrade.
duckplyr is now in the tidyverse—and it’s fast. Really fast. 🧵
Lorenzo Lindo retweeted
Just published @ScienceMagazine
Engineering T cells within the body, a big step forward for treating cancer and autoimmune diseases, as demonstrated in animal models
science.org/doi/10.1126/scie…
science.org/doi/10.1126/scie…
Lorenzo Lindo retweeted
1/ If you're in bioinformatics, you're staring at matrices all day.
RNA-seq? Gene x sample.
scRNA-seq? Gene x cell.
Everything is a matrix.
But I never learned how to think in matrices. And I regret it.
Lorenzo Lindo retweeted
#mmsm @JCO_ASCO New definition of high risk multiple myeloma by IMWG
➡️ascopubs.org/doi/10.1200/JCO…
Summary 👇
